The CRASH-19 study is evaluating aspirin, the angiotensin receptor blocker losartan, and simvastatin to see if they provide more effective cardiac and pulmonary protection to hospitalized COVID-19 patients compared with the regular standard of supportive care provided to COVID-19 patients in hospital.
Primary objective: To assess the effectiveness and safety of supportive care interventions for patients hospitalised with suspected or confirmed acute COVID-19 infection.
Type of study: Interventional; Phase III, treatment
Treatment tested: Aspirin, Losartan and Simvastatin
Countries: Confirmed – Pakistan and Nigeria, with possible extension to Central and South America
Sample size: 10,000
Study participants: Hospitalized patients aged 40+ years with confirmed or suspected COVID-19 not requiring mechanical ventilation.
Study status: Recruiting
Last updated: June 2020
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.